JAK1 and atopic eczema: JAK inhibitors such as upadacitinib (selective JAK1 inhibitor), abrocitinib (preferred JAK1 inhibitor), and baricitinib (A JAK1/2 inhibitor) have been proven to rapidly alleviate itching and skin lesions in atopic dermatitis, and surpassing conventional immunosuppressants [254, 255].